Trials / Active Not Recruiting
Active Not RecruitingNCT06488170
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab | As provided in real world clinical practice. |
Timeline
- Start date
- 2024-04-04
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2024-07-05
- Last updated
- 2025-06-24
Locations
7 sites across 1 country: Czechia
Source: ClinicalTrials.gov record NCT06488170. Inclusion in this directory is not an endorsement.